BioCentury
ARTICLE | Clinical News

ABX-EGF: Phase II

June 9, 2003 7:00 AM UTC

Interim data from a U.S. Phase II trial in 40 evaluable refractory metastatic colorectal cancer patients receiving ABX-EGF monotherapy showed 4 partial responses and 22 cases of stable disease after 8...